Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are trading lower by 62% to $2.07 during Monday's pre-market session. The company on Monday morning received feedback from the U.S. Food and Drug Administration (FDA) regarding their new drug application (NDA) for reproxalap, intended for treating dry eye disease.
The FDA says it identified significant issues with the clinical data supporting the drug's effectiveness for this indication.
See Also: Drug Retailer Rite Aid Grappling With ...
ALDX) Stock Is Getting Obliterated>Full story available on Benzinga.com